Drug intelligence / Profile preview

BR108

Development stage: Phase 1
Lead developer: BioRay Pharmaceutical
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

BR108 is an ADCC-enhanced monoclonal antibody that targets CD70, a cell surface antigen. It is designed to inhibit CD70 and mediate antibody-dependent cell-mediated cytotoxicity (ADCC), leading to the effective killing of various types of CD70-expressing cells. The drug has demonstrated superior binding affinity to CD70 in preclinical studies. BR108 was initially developed by Hisun Bio Pharmaceutical and is being investigated for the treatment of hematologic malignancies, with its highest development phase being Phase 1 clinical trials in China[1][2][3].

Targets

CD70 (Cluster of Differentiation 70)

Beyond the preview

Go deeper on BR108.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BR108.

Explore the full profile